Fasching P, Decker T, Guderian G, Heim J, Jackisch C, Lueck HJ, Lueftner D, Marme F, Reimer T, Woeckel A (2018)
Publication Type: Conference contribution
Publication year: 2018
Publisher: OXFORD UNIV PRESS
City/Town: OXFORD
Conference Proceedings Title: ANNALS OF ONCOLOGY
DOI: 10.1093/annonc/mdy271.275
APA:
Fasching, P., Decker, T., Guderian, G., Heim, J., Jackisch, C., Lueck, H.-J.,... Woeckel, A. (2018). Real-world effectiveness of ribociclib 1 aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study. In ANNALS OF ONCOLOGY. Munich, DE: OXFORD: OXFORD UNIV PRESS.
MLA:
Fasching, Peter, et al. "Real-world effectiveness of ribociclib 1 aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study." Proceedings of the 43rd ESMO Congress (ESMO), Munich OXFORD: OXFORD UNIV PRESS, 2018.
BibTeX: Download